- Home
- ALZN vs GSIW Comparison
ALZN vs GSIW Comparison
Compare ALZN & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALZN
- GSIW
- Stock Information
- Founded
- ALZN 2016
- GSIW 2016
- Country
- ALZN United States
- GSIW Hong Kong
- Employees
- ALZN N/A
- GSIW N/A
- Industry
- ALZN Medicinal Chemicals and Botanical Products
- GSIW
- Sector
- ALZN Health Care
- GSIW
- Exchange
- ALZN Nasdaq
- GSIW Nasdaq
- Market Cap
- ALZN 7.5M
- GSIW 8.1M
- IPO Year
- ALZN 2021
- GSIW 2023
- Fundamental
- Price
- ALZN $2.35
- GSIW $0.15
- Analyst Decision
- ALZN Strong Buy
- GSIW
- Analyst Count
- ALZN 1
- GSIW 0
- Target Price
- ALZN $42.00
- GSIW N/A
- AVG Volume (30 Days)
- ALZN 132.3K
- GSIW 5.7M
- Earning Date
- ALZN 12-11-2025
- GSIW 01-01-0001
- Dividend Yield
- ALZN N/A
- GSIW N/A
- EPS Growth
- ALZN N/A
- GSIW N/A
- EPS
- ALZN N/A
- GSIW N/A
- Revenue
- ALZN N/A
- GSIW $5,368,221.00
- Revenue This Year
- ALZN N/A
- GSIW N/A
- Revenue Next Year
- ALZN N/A
- GSIW N/A
- P/E Ratio
- ALZN N/A
- GSIW N/A
- Revenue Growth
- ALZN N/A
- GSIW 283.23
- 52 Week Low
- ALZN $2.06
- GSIW $0.09
- 52 Week High
- ALZN $15.21
- GSIW $1.79
- Technical
- Relative Strength Index (RSI)
- ALZN 48.08
- GSIW 45.56
- Support Level
- ALZN $2.27
- GSIW $0.15
- Resistance Level
- ALZN $2.56
- GSIW $0.16
- Average True Range (ATR)
- ALZN 0.16
- GSIW 0.02
- MACD
- ALZN 0.01
- GSIW 0.00
- Stochastic Oscillator
- ALZN 50.71
- GSIW 68.15
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.